Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application

MJ Millan - Pharmacology & therapeutics, 2006 - Elsevier
Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

Generalized anxiety disorder

K Rowa, S Waechter, HK Hood… - … History, Diagnosis, and …, 2017 - Wiley Online Library
Generalized anxiety disorder (GAD) is characterized by excessive worry about a variety of
topics. In addition to the presence of uncontrollable and persistent worry, the diagnosis of …

[HTML][HTML] Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical …

P Bradley, M Shiekh, V Mehra, K Vrbicky… - Journal of psychiatric …, 2018 - Elsevier
The objective of this study was to evaluate the effect of pharmacogenetics-guided treatment
on patients diagnosed with depression and/or anxiety, in a diverse set of clinical settings, as …

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

MJ Millan - Therapies, 2005 - Elsevier
Abstract Serotonin (5-HT) 2C receptors play an important role in the modulation of
monoaminergic transmission, mood, motor behaviour, appetite and endocrine secretion …

Pregabalin: a new neuromodulator with broad therapeutic indications

BF Shneker, JW McAuley - Annals of Pharmacotherapy, 2005 - journals.sagepub.com
OBJECTIVE To review pregabalin's pharmacology, pharmacokinetics, efficacy, and adverse
effects in the treatment of neuropathic pain, epilepsy, and anxiety. DATA SOURCES A …

Pharmacological treatment for generalized anxiety disorder in adults: an update

JA Reinhold, K Rickels - Expert opinion on pharmacotherapy, 2015 - Taylor & Francis
Introduction: Modest response and remission rates for the selective serotonin reuptake
inhibitors and the serotonin-norepinephrine reuptake inhibitors, coupled with mounting …

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

J Hartford, S Kornstein, M Liebowitz… - International Clinical …, 2007 - journals.lww.com
This study examined the efficacy and tolerability of duloxetine 60–120 mg/day for the
treatment of patients with generalized anxiety disorder. This was a multicenter, randomized …

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible‐dose, progressive‐titration, placebo‐controlled trial

M Rynn, J Russell, J Erickson, MJ Detke… - Depression and …, 2008 - Wiley Online Library
Generalized anxiety disorder (GAD), a prevalent and chronic illness, is associated with
dysregulation in both serotonergic and noradrenergic neurotransmission. Our study …

Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials

JLR Martin, M Sainz-Pardo… - Journal of …, 2007 - journals.sagepub.com
No systematic review or meta-analysis using a hard outcome has been conducted on the
role of benzodiazepines for generalized anxiety disorder (GAD). The objective of this study …

Treatment of anxiety disorders in epilepsy: an evidence‐based approach

M Mula - Epilepsia, 2013 - Wiley Online Library
During recent years growing attention has been paid to psychiatric comorbidities in epilepsy.
However, anxiety disorders still remain underrecognized and undertreated. This is largely …